Posted by Michael Wonder on 23 Oct 2019
Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis
22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients.
Patients living in Quebec will now have access, through the Régie de l'assurance maladie Québec (RAMQ), to Dupixent (dupilumab).
Dupixent is used to treat adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
It is anticipated that additional jurisdictions will be adding Dupixent on their public formularies in the near future.
